Want to see HK:2185 full AI Analyst Report?
Top Page
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
(2185)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$1.50
▼(-73.73% Downside)
Action:Reiterated
Date:09/19/26
The score is pressured primarily by weak financial performance—ongoing heavy losses and persistent negative free cash flow outweigh the benefit of low leverage. Technicals further detract as the stock remains in a pronounced downtrend with negative momentum signals. Valuation provides only limited support because losses (negative P/E) reduce the usefulness of traditional valuation metrics and no dividend yield is available.
Positive Factors
Revenue Rebound
The sharp 2025 revenue rebound shows that the company has demonstrated some ability to generate renewed commercial activity. If this recovery is sustained, a larger revenue base could improve operating leverage and provide a foundation for eventual progress toward a viable business model.
Negative Factors
Deep Unprofitability
Negative gross profit means the reported revenue base is not yet covering direct costs, while substantial operating losses show that overhead and development spending remain difficult to absorb. Without a durable improvement in margins, revenue growth alone may not translate into earnings or financial self-sufficiency.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Rebound
The sharp 2025 revenue rebound shows that the company has demonstrated some ability to generate renewed commercial activity. If this recovery is sustained, a larger revenue base could improve operating leverage and provide a foundation for eventual progress toward a viable business model.
Read all positive factors
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H (2185) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$348.09M
Dividend YieldN/A
Average Volume (3M)74.63K
Price to Earnings (P/E)―
Beta (1Y)2.26
Revenue Growth90.73%
EPS Growth12.93%
CountryHK
Employees63
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.31
Shares Outstanding235,703,410
10 Day Avg. Volume43,540
30 Day Avg. Volume74,630
Financial Highlights & Ratios
PEG Ratio0.84
Price to Book (P/B)2.91
Price to Sales (P/S)28.92
P/FCF Ratio-17.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)HK$2.07B
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Based in the People's Republic of China, Shanghai Bio-heart Biological Technology Co., Ltd. is a medical technology firm specializing in interventional cardiovascular devices. Its core business revolves around delivering bioresorbable scaffolds (B...
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
68
Positive
Cash Flow
17
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 37.85M | 43.77M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -868.26K | -157.81K | 0.00 | -23.60M | -24.25M | -13.27M |
| EBITDA | -66.27M | -52.13M | -44.54M | -148.21M | -237.34M | -400.88M |
| Net Income | -74.33M | -68.24M | -87.94M | -175.89M | -204.24M | -361.45M |
Balance Sheet | ||||||
| Total Assets | 790.68M | 832.83M | 733.78M | 817.90M | 981.52M | 1.11B |
| Cash, Cash Equivalents and Short-Term Investments | 237.83M | 248.63M | 202.39M | 369.44M | 451.32M | 708.53M |
| Total Debt | 180.43M | 12.73M | 8.28M | 1.76M | 18.11M | 22.45M |
| Total Liabilities | 211.92M | 220.47M | 53.24M | 44.04M | 66.47M | 80.04M |
| Stockholders Equity | 402.08M | 435.00M | 660.47M | 748.41M | 883.21M | 995.69M |
Cash Flow | ||||||
| Free Cash Flow | -78.90M | -72.91M | -166.69M | -66.74M | -170.65M | -147.28M |
| Operating Cash Flow | -69.25M | -65.48M | -119.55M | -49.03M | -140.62M | -105.45M |
| Investing Cash Flow | -24.53M | -39.78M | -46.03M | -28.86M | -100.69M | -33.73M |
| Financing Cash Flow | 224.31K | -1.74M | -2.44M | -5.82M | -35.18M | 383.68M |
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Technical Analysis
Negative
5.71
Price Trends
1.91
Negative
2.39
Negative
3.75
Negative
Market Momentum
-0.16
Negative
30.14
Neutral
20.04
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2185, the sentiment is Negative. The current price of 5.71 is above the 20-day moving average (MA) of 1.55, above the 50-day MA of 1.91, and above the 200-day MA of 3.75, indicating a bearish trend. The MACD of -0.16 indicates Negative momentum. The RSI at 30.14 is Neutral, neither overbought nor oversold. The STOCH value of 20.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2185.
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$29.97B | 71.83 | 15.94% | ― | 48.04% | 166.72% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$2.02B | 21.04 | 48.25% | ― | 88.38% | ― | |
48 Neutral | HK$7.40B | -65.60 | -9.45% | ― | 68.12% | 81.84% | |
44 Neutral | HK$348.09M | -3.76 | -17.76% | ― | 90.73% | 12.93% | |
44 Neutral | HK$835.33M | -11.13 | 85.52% | ― | -55.22% | 57.76% | |
42 Neutral | HK$970.43M | -8.81 | -39.21% | ― | ― | ― |
* Healthcare Sector Average
HK:2185
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
1.37
-6.52
-82.68%
HK:2171
CARsgen Therapeutics Holdings Ltd.
12.33
-9.43
-43.34%
HK:2181
Mabpharm Limited
0.51
-0.13
-19.84%
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
71.50
43.98
159.81%
HK:2496
Wuhan YZY Biopharma Co., Ltd. Class H
3.19
-3.60
-53.02%
HK:2898
Sunho Biologics,Inc.
6.39
-1.31
-17.01%
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Corporate Events
Shanghai Bio-heart Says Director’s Regulatory Warning Won’t Hit Operations
Sep 16, 2026
Shanghai Bio-heart Biological Technology Co., Ltd. has disclosed that independent non-executive director Mr. Chen Yiqing received a formal warning letter from the Tianjin Securities Regulatory Bureau related to his former role at Zhongyuan Concord...
Shanghai Bio-heart Strikes Strategic Pact to Commercialise Bioabsorbable Coronary Stent
Sep 14, 2026
Shanghai Bio-heart Biological Technology Co., Ltd. has signed a strategic cooperation agreement with Shanghai Shenqi Medical Technology Co., Ltd. to jointly advance the commercialisation and clinical application of its BioHeart bioabsorbable rapam...
AngioCare hires renal denervation veteran to drive global Iberis therapy push
Sep 7, 2026
Shanghai Bio-heart’s subsidiary AngioCare has appointed veteran cardiovascular and metabolic disease specialist Giorgio Gobbi as Vice President, Global Therapy Development, to lead global therapy development for the Iberis Renal Denervation ...
Shanghai Bio-Heart Sets October EGM to Strengthen Board Independence
Sep 4, 2026
Shanghai Bio-Heart Biological Technology Co., Ltd., a Hong Kong-listed PRC biotech firm focused on medical technology, operates through a Class H share structure and is governed by a board led by chairman and executive director Philip Li Wang. Its...
Shanghai Bio-Heart Narrows Market Path With New Stent Approval Amid Wider Interim Loss
Aug 26, 2026
Shanghai Bio-Heart Biological Technology Co., Ltd., a Chinese cardiovascular device maker, develops and commercializes interventional products such as bioabsorbable drug-eluting stents and the Iberis system for ischemic heart disease. The company ...
Shanghai Bio-Heart reshapes board as independent director exits
Aug 26, 2026
Shanghai Bio-Heart Biological Technology has announced the resignation of independent non-executive director Yiqing Chen, who is stepping down to focus on other business commitments but will remain in post until shareholders approve a successor. C...
Shanghai Bio-heart Sets Board Meeting to Review Interim Results and Possible Dividend
Aug 14, 2026
Shanghai Bio-heart Biological Technology Co., Ltd., a Hong Kong-listed Chinese biotech firm under stock code 2185, operates in the biological and medical technology industry with a focus on innovative healthcare products and services in China and ...
Shanghai Bio-Heart Wins NMPA Nod for Bioabsorbable Coronary Stent
Jul 1, 2026
Shanghai Bio-Heart Biological Technology has received approval from China’s National Medical Products Administration for its Bioheart bioabsorbable drug-eluting stent system, indicated for patients with ischemic heart disease caused by nativ...
Shanghai Bio-heart Shareholders Approve All AGM Resolutions and Governance Changes
Jun 26, 2026
Shanghai Bio-heart Biological Technology Co., Ltd. held its 2025 annual general meeting in Shanghai on June 26, 2026, with shareholders representing about 8.71% of issued shares in attendance. All directors participated in person or electronically...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.